Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Deerfield Management Discloses Stake in Post-IPO Auspex Pharmaceuticals Inc (ASPX)

James E. Flynn‘s Deerfield Management has revealed holding shares of Auspex Pharmaceuticals Inc (NASDAQ:ASPX), a company that went public today, on February 5. Deerfield reported ownership of around 1.29 million common shares, held via class E preferred stock. The securities can be converted into shares of common stock on the basis of 0.222 shares of Common Stock per one unit of Preferred Stock.

Auspex

According to the terms of the IPO, Auspex Pharmaceuticals Inc (NASDAQ:ASPX) intended to sell 6.0 million shares at a price of $12 apiece. In this way following the IPO, the preferred stock of the company will be converted and the total amount of outstanding shares amounts to around 21.53 million. The net proceeds from the offering are planned to be used for the development of Auspex’s SD-809, a novel drug discovered by the company, and for which it holds worldwide rights. The drug is the main product of the company, and since it has not been approved by the FDA it represents a major risk that will severely impact Auspex Pharmaceuticals Inc (NASDAQ:ASPX)’s business.

Despite the risk associated with the weak financial results and the company’s dependence on a single product, the IPO was well received by the market, the stock of Auspex Pharmaceuticals Inc (NASDAQ:ASPX) gaining around 18% in the morning trading.

Aside from Auspex Pharmaceuticals Inc (NASDAQ:ASPX), Deerfield reported recently about another biopharmaceutical “emerging growth” company that went public a couple of days ago, Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). The fund reported holding around 2.12 million shares, which have been obtained through the conversion of the preferred stock held previously to the IPO and the acquisition of additional units of common stock.

Both investments disclosed lately by Deerfield, Auspex Pharmaceuticals Inc (NASDAQ:ASPX) and Dicerna come in line with the fund’s targets. Deerfield prefers to focus on healthcare companies and funds Research & Development among other things.

Disclosure: none

Recommended Reading:

Deerfield Management & Brookside Capital Revealed Significant Stakes in Newly Public Dicerna Pharmaceuticals Inc (DRNA)

Sanford J. Colen’s Apex Capital’s Top Picks Include Netflix, Inc. (NFLX) & eBay Inc (EBAY) Among Others

Michael Messner’s Seminole Capital Top Picks From the Latest 13F

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...